State of the art clinical efficacy and safety evaluation of N-acetylcarnosine dipeptide ophthalmic prodrug. Principles for the delivery, self-bioactivation, molecular targets and interaction with a highly evolved histidyl-hydrazide structure in the treatment and therapeutic management of a group of sight-threatening eye diseases

Current Clinical Pharmacology

Volumn 4, Issue 1, 2009, Pages 4-37

  Babizhayev, Mark A ^a,c   Kasus Jacobi, Anne ^b  

^a Innovative Vision Products Incorporated   (United States)

^b UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^c Innovative Vision Products Inc   (Russian Federation)

Author keywords

Age related ophthalmic diseases; Aldehyde scavenging and transglycation activities; Antioxidant activity; Cataract; Corneal metabolism; Diabetic ocular complications; Disability glare; Halometer; Halos; Histidine hydrazide carnosine analogs; Home health care; L carnosine; N acetylcarnosine lubricant eye drops; Ophthalmic bioactivated prodrug and codrug formulations; Visual acuity

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AGENTS ACTING ON THE EYE; ASCORBIC ACID; CAN C; CARCININE; CARNOSINE; D SMILE; EYE DROPS; IRON; IVP C; N ACETYLCARNOSINE; PLACEBO; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTIOXIDANT; DRUG DERIVATIVE; HISTIDINE; HISTIDYLHYDRAZINE; HYDRAZINE DERIVATIVE; LIPOSOME; LUBRICATING AGENT; N-ACETYLCARNOSINE; PRODRUG;

ALLERGY; ANTIOXIDANT ACTIVITY; BLURRED VISION; CARBON NUCLEAR MAGNETIC RESONANCE; CATARACT; CATARACTOGENESIS; CENTRAL RETINA VEIN OCCLUSION; CLINICAL TRIAL; COMPARATIVE STUDY; CONJUNCTIVAL HYPEREMIA; CONTACT LENS; CORNEA ACIDOSIS; CORNEA DISEASE; DIABETIC RETINOPATHY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRY EYE; EYE BURNING; EYE DISCHARGE; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; FOREIGN BODY; GLARE; GLYCATION; GOOD MANUFACTURING PRACTICE; HUMAN; LASER EPITHELIAL KERATOMILEUSIS; LIPID PEROXIDATION; LIPOSOMAL DELIVERY; MOLECULAR INTERACTION; NEOVASCULAR GLAUCOMA; NONHUMAN; OPEN ANGLE GLAUCOMA; OXIDATIVE STRESS; PATIENT; PHOTOPHOBIA; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROTEIN MODIFICATION; PUNCTATE KERATITIS; RETINA MACULOPATHY; REVIEW; STRUCTURE ACTIVITY RELATION; VISUAL ACUITY; VISUAL IMPAIRMENT; AGED; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GLYCOSYLATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; CARNOSINE; CATARACT; CONTACT LENSES; DOUBLE-BLIND METHOD; DRUG DELIVERY SYSTEMS; FEMALE; GLYCOSYLATION; GLYCOSYLATION END PRODUCTS, ADVANCED; HISTIDINE; HUMANS; HYDRAZINES; LIPID PEROXIDATION; LIPOSOMES; LUBRICANTS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; OXIDATIVE STRESS; PRODRUGS; VISUAL ACUITY;

EID: 65649102280     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488409787236074     Document Type: Review

References (89)

1. Quillen DA. Common causes of vision loss in elderly patients. Am Fam Physician 1999; 60(1): 99-108.
2. West SK. Looking forward to 20/20: a focus on the epidemiology of eye diseases. Epidemiol Rev 2000; 22: 64-70.
3. Brian G, Taylor HR. Cataract blindness: challenge for the 21st century. Bull World Health Organ 2001; 79: 249-256.
4. Yorston D. Cataract complications. Commun Eye Health J 2008; 65: 1-3.
5. Gogate PM, Kulkarni SR, Krishnaiah S, et al. Safety and efficacy of phacoemulsification compared with manual smallincision cataract surgery by a randomized controlled clinical trial: six-week results. Ophthalmology 2005; 112: 869-74.
6. Babizhayev MA, Deyev AI, Linberg LF. Lipid peroxidation as a possible cause of cataract. Mech Ageing Develop 1988; 44(1): 69-89.
7. Babizhayev MA, Deyev AI, Yermakova VN, Brikman IV, Bours J. Lipid peroxidation and cataracts: N-acetylcarnosine as a therapeutic tool to manage age-related cataracts in human and in canine eyes. Drugs Res Develop 2004; 5(3): 125-39.
8. Babizhayev MA, Deyev AI. Free radical oxidation of lipids and thiol groups in the formation of a cataract. Biofizika 1986; 31(1): 109-14.
9. Babizhayev MA, Deyev AI. Lens opacity induced by lipid peroxidation products as a model of cataract associated with retinal disease. Biochim Biophys Acta 1989; 1004(1): 124-33.
10. Yu T, Robotham JL, Yoon Y. Increased production of reactive oxygen species in hyperglycemic conditions requires dynamic change of mitochondrial morphology. Proc Natl Acad Sci USA 2006; 21; 103(8): 2653-58.
11. Ansari NH, Wang L, Erwin AA, Church DF. Glucose-dependent formation of free radical species in lens homogenate. Biochem Mol Med 1996; 59(1): 68-71.
12. Sell DR, Nagaraj RH, Grandhee SK, et al. Pentosidine: a molecular marker for the cumulative damage to proteins in diabetes, aging, and uremia. Diabetes Metab Rev 1991; 7(4): 239-51.
13. Wautier JL, Guillausseau PJ. Advanced glycation end products, their receptors and diabetic angiopathy. Diabetes Metab 2001; 27(5 Pt 1): 535-42. Comment in: Diabetes Metab 2003; 29(1): 86-7.
14. Dyer DG, Dunn JA, Thorpe SR, et al. Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 1993; 91(6): 2463-9.
15. Sensi M, Pricci F, Pugliese G, et al. Role of advanced glycation end-products (AGE) in late diabetic complications. Diabetes Res Clin Pract 1995; 28(1): 9-17.
16. Babizhayev MA, Seguin M-C, Gueyne J, Evstigneeva RP, Ageyeva EA, Zheltukhina GA. L-Carnosine (β-alanyl-L-histidine) and carcinine (β-alanylhistamine) act as natural antioxidants with hydroxyl-radical-scavenging and lipid peroxidase activities. Biochem J 1994; 304: 509-16.
17. Babizhayev MA. Antioxidant activity of L-carnosine, a natural histidine-containing dipeptide in crystalline lens. Biochim Biophys Acta 1989; 1004: 363-71.
18. Babizhayev MA, Yermakova VN, Sakina NL, Evstigneeva RP, Rozhkova EA, Zheltukhina GA. N-acetylcarnosine is a prodrug of L-carnosine in ophthalmic application as antioxidant. Clin Chim Acta 1996; 254: 1-21.
19. Guiotto A, Ruzza P, Babizhayev MA, Calderan A. Malondialdehyde scavenging and aldose-derived Schiff bases' transglycation properties of synthetic histidyl-hydrazide carnosine analogs. Bioorg Med Chem 2007; 15(18): 6158-63.
20. Mannion AF, Jakeman PM, Dunnett M, Harris RC, Willan PL. Carnosine and anserine concentrations in the quadriceps femoris muscle of healthy humans. Eur J Appl Physiol Occup Physiol 1992; 64(1): 47-50.
21. Abe H. Role of histidine-related compounds as intracellular proton buffering constituents in vertebrate muscle. Biochemistry (Mosc) 2000; 65(7): 757-65.
22. McFarland GA, Holliday R. Retardation of the senescence of cultured human diploid fibroblasts by carnosine. Exp Cell Res 1994; 212(2): 167-75.
23. Hipkiss AR. Carnosine, a protective, anti-ageing peptide? Int J Biochem Cell Biol 1998; 30(8): 863-8
24. Aldini G, Carini M, Beretta G, Bradamante S, Facino RM. Carnosine is a quencher of 4-hydroxy-nonenal: through what mechanism of reaction? Biochem Biophys Res Commun 2002; 298(5): 699-706.
25. Aldini G, Granata P, Carini M. Detoxification of cytotoxic alpha, beta-unsaturated aldehydes by carnosine: characterization of conjugated adducts by electrospray ionization tandem mass spectrometry and detection by liquid chromatography/mass spectrometry in rat skeletal muscle. J Mass Spectrometry 2002; 37(12): 1219-28.
26. Babizhayev MA, Deyev AI, Yermakova VN, Remenschikov VV, Bours J. Revival of the lens transparency with N-acetylcarnosine. Curr Drug Ther 2006; 1: 91-116.
27. Babizhayev MA. Ophthalmic pharmacology of N-acetylcarnosine lubricant eye drops. J Pharmacol Toxicol 2006; 1(3): 201-33.
28. Horinishi H, Grillo M, Margolis FL. Purification and characterization of carnosine synthetase from mouse olfactory bulbs. J Neurochem 1978; 31(4): 909-19.
29. Babizhayev MA. Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. Drug Dev Ind Pharm 2008; 34(10): 1071-89.
30. Lenney JF, Peppers SC, Kucera-Orallo CM, George RP. Characterization of human tissue carnosinase. Biochem J 1985; 228(3): 653-60.
31. Babizhayev MA, Costa BE. Composizioni farmaceutiche contenenti N-acetilcarnosina per il trattamento della cataratta. Italian Patent A61K gruppo 37/00 20122 MI, Priority 1993; Oct. 15.
32. Babizhayev MA, Bozzo Costa E. Pharmaceutical compositions containing N-acetylcarnosine for the treatment of cataract. Patent PCT/EP 94/03340 SCB 238 PCT, Oct. 10, 1994.
33. Babizhayev MA. Method for topical treatment of eye disease and composition and device for said treatment. PCT Patent Application. International Publication Number WO 2004/028536 A1. International Publication Date: 8 April 2004.
34. Babizhayev MA, Meguro K. Combined use of carnosinase inhibitor with l-carnosines and composition. 2004; WO 2004/064866 PCT/JP2004/000351. Filed 20 January 2003 (20.01.2003).
35. Babizhayev MA, Deyev AI, Yermakova VN, et al. Image analysis and glare sensitivity in human age-related cataracts. Clin Exp Optomet 2003; 86(3): 157-72.
36. Babizhayev MA. Glare disability and driving safety. Ophthal Res 2003; 35(1): 19-25.
37. Babizhayev MA, Deyev AI, Yermakova VN, et al. Efficacy of N-acetylcarnosine in the treatment of cataracts. Drugs Res Develop 2002; 3(2): 87-103.
38. Babizhayev MA, Seguin M-C. Process of assessment of ocular dysfunctions and implementation devices of this process. US Patent No. 6,007,203. Date of patent: December 28, 1999.
39. Babizhayev MA, Yermakova VN, Deyev AI, Seguin M-C. Imidazole-containing peptidomimetic NACA as a potent drug for the medicinal treatment of age-related cataract in humans. J Anti-Aging Med 2000; 3: 43-62.
40. Babizhayev MA. Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. Rejuven Res 2004; 7: 186-98.
41. Babizhayev MA, Deyev AI, Yermakova VN, et al. Goldman IM. N-Acetylcarnosine, a natural histidine-containing dipeptide, as a potent ophthalmic drug in treatment of human cataracts. Peptides 2001; 22: 979-94.
42. Babizhayev MA, Costa BE. Lipid peroxide and reactive oxygen species generating systems of the crystalline lens. Biochim Biophys Acta 1994; 1225: 326-37.
43. Szwergold BS. Carnosine and anserine act as effective transglycating agents in decomposition of aldose-derived Schiff bases. Biochem Biophys Res Commun 2005; 336(1): 36-41.
44. Bando K, Shimotsuji T, Toyoshima H, Hayashi C, Miyai K. Fluorometric assay of human serum carnosinase activity in normal children, adults and patients with myopathy. Ann Clin Biochem 1984; 21 (Pt 6): 510-14.
45. Owsley C, Stalvey BT, Wells J, Sloane ME, McGwin G Jr. Visual risk factors for crash involvement in older drivers with cataract. Arch Ophthalmol 2001; 119: 881-87.
46. Ferris FL 3rd, Kassoff A, Bresnick GH, Bailey I. New visual acuity charts for clinical research. Am J Ophthalmol 1982; 94: 91-6.
47. Ferris FL, Sperduto RD. Standardized illumination for visual acuity testing in clinical research. Am J Ophthalmol 1982; 94: 97-8.
48. Babizhayev MA. Failure to withstand oxidative stress induced by phospholipid hydroperoxides as a possible cause of the lens opacities in systemic diseases and ageing. Biochim Biophys Acta 1996; 1315: 87-99.
49. Jackson MC, Kucera CM, Lenney JF. Purification and properties of human serum carnosinase. Clin Chim Acta 1991; 196(2-3): 193-205.
50. Rosenberg A. Purification and some properties of carnosinase of swine kidney. Arch Biochem Biophys 1960; 88: 83-93.
51. Lenney JF. Specificity and distribution of mammalian carnosinase. Biochim Biophys Acta 1976; 429(1): 214-9.
52. Teufel M, Saudek V, Ledig JP, et al. Sequence identification and characterization of human carnosinase and a closely related non-specific dipeptidase. J Biol Chem 2003; 278(8): 6521-31.
53. Unno H, Yamashita T, Ujita S, et al. Structural basis for substrate recognition and hydrolysis by mouse carnosinase CN2. J Biol Chem 2008 Oct 3; 283(40): 27289-99.
54. Bonanno JA. Contact lens induced corneal acidosis. CLAO J 1996; 22: 70-4.
55. Boldyrev AA Carnosine. Biological significance and possibilities for application in medicine. Moscow State University, Moscow 1998; p. 180.
56. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ 2003; 22: 151-85.
57. Owens J. 2006 drug approvals: finding the niche. Nat Rev Drug Discov 2007; 6: 99-101.
58. Traynor K. Recap of FDA product approvals -2002. Am J Health Syst Pharm 2003; 60: 310-11.
59. Traynor K. New drug and biological product approvals, 2003. Am J Health Syst Pharm 2004; 61: 338-40.
60. Traynor K. New drug and biological product approvals, 2004. Am J Health Syst Pharm 2005; 62: 348-50.
61. Traynor K. New drug and biologic product approvals, 2005. Am J Health Syst Pharm 2006; 63: 304-6.
62. Traynor K. New drug and biological product approvals, 2006. Am J Health Syst Pharm 2007; 64: 342-4.
63. Balbach S, Korn C. Pharmaceutical evaluation of early development candidates "the 100 mg approach". Int J Pharm 2004; 275(1-2): 1-12.
64. Hageman MJ. Solubility, Solubilization and Dissolution in Drug Delivery During Lead Optimization. In: Borchardt RT, Kerns EH, Hageman MJ, Thakker DR, Stevens JL, Eds. Optimizing the "DrugLike" Properties of Leads in Drug Discovery, Springer Science + Business Media: New York, 2006; pp. 99-130.
65. Oprea TI. Current trends in lead discovery: are we looking for the appropriate properties? Mol Divers 2002; 5: 199-208.
66. Boldyrev AA, Dupin AM, Bunin AYa, Babizhayev MA, Severin SE. The antioxidative properties of carnosine, a natural histidine containing dipeptide. Biochem Int 1987; 15: 1105-13.
67. Kang JH, Kim KS, Choi SY, Kwon HY, Won MH, Kang TC. Protective effects of carnosine, homocarnosine and anserine against peroxyl radical-mediated Cu,Zn-superoxide dismutase modification. Biochim Biophys Acta 2002; 1570: 89-96.
68. Hipkiss AR, Preston JE, Himswoth DT, Worthington VC, Abbot NJ. Protective effects of carnosine against malondialdehyde-induced toxicity towards cultured rat brain endothelial cells. Neurosci Lett 1997; 238(3): 135-8.
69. Hipkiss AR, Worthington VC, Himsworth DT, Herwig W. Protective effects of carnosine against protein modification mediated by malondialdehyde and hypochlorite. Biochim Biophys Acta 1998; 1380(1): 46-54.
70. Zhou S, Decker EA. Ability of carnosine and other skeletal muscle components to quench unsaturated aldehydic lipid oxidation products. J Agric Food Chem 1999; 47(1): 51-5.
71. Hobart LJ, Seibel I, Yeargans GS, Seidler NW. Anti-crosslinking properties of carnosine: Significance of histidine. Life Sci 2004; 75: 1379-89.
72. Brownson C, Hipkiss AR. Carnosine reacts with a glycated protein. Free Radical Biol Med 2000; 28(10): 1564-70.
73. Hipkiss AR, Chana H. Carnosine protects proteins against methylglyoxal-mediated modifications. Biochem Biophys Res Commun 1998; 248(1): 28-32.
74. Hipkiss AR, Michaelis J, Syrris P. Non-enzymatic glycosylation of the dipeptide L-carnosine, a potential anti-protein-cross-linking agent. Feder Eur Biochem Soc Lett 1995; 371(1): 81-5.
75. Hipkiss AR, Michaelis J, Syrris P, Kumar S, Lam Y. Carnosine protects proteins against in vitro glycation and cross-linking. Biochem Soc Transactions 1994; 22(4): 399S.
76. Hipkiss AR. Glycation, ageing and carnosine: are carnivorous diets beneficial? Mechan Ageing Develop 2005; 126(10): 1034-9.
77. Taylor A, Davies KJ. Protein oxidation and loss of protease activity may lead to cataract formation in the aged lens. Free Radical Biol Med 1987; 3: 371-7.
78. Murakami K, Jahngen JH, Lin SW, Davies KJ, Taylor A. Lens proteasome shows enhanced rates of degradation of hydroxyl radical modified alpha-crystallin. Free Radical Biol Med 1990; 8: 217- 22.
79. Seidler NW, Yeargans GS, Morgan TG. Carnosine disaggregates glycated alpha-crystallin: an in vitro study. Arch Biochem Biophys 2004; 427: 110-5.
80. Yamagishi S-I, Nakamura K, Imaizumi T. Advanced glycation end products (AGEs) and diabetic vascular complications. Curr Diabetes Rev 2005; 1: 93-106.
81. Al-Ghananeem AM, Crooks PA. Phase I and Phase II ocular metabolic activities and the role of metabolism in ophthalmic prodrug and codrug design and delivery. Molecules 2007; 12: 373-388.
82. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997; 23: 3-25.
83. Waterbeemd Hvd. Quantitative Structure-Absorption Relationships. In: Testa B, Waterbeemd Hvd, Folkers G, Guy R Eds. Pharmacokinetic Optimization in Drug Research, Verlag Helvetica Chimica Acta and Wiley-VCH: Ochsenfurt-Hohestadt, 2001.
84. Sugiyama Y. Druggability: selecting optimized drug candidates. Drug Discov Today 2005; 10: 1577-9.
85. Di L, Kerns EH. Application of pharmaceutical profiling assays for optimization of drug-like properties. Curr Opin Drug Discov Develop 2005; 8: 495-504.
86. Kerns EH, Di L. Pharmaceutical profiling in drug discovery. Drug Discov Today 2003; 8: 316-23.
87. Babizhayev MA. Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products. Life Sci 2006; 78(20): 2343-57.
88. Muranov KO, Dizhevskaia AK, Boldyrev AA, et al. Search for chaperon-like anticataract drugs, the antiaggregants of lens crystallins. Communication. 1. Chaperon-like activity of N-acetyl carnosine dipeptide: in vitro study on a model of ultraviolet-induced aggregation of betaL-crystallin. Vestn Oftalmol 2008; 124(2): 3-6.
89. Hipkiss AR, Brownson C, Bertani MF, Ruiz E, Ferro A. Reaction of carnosine with aged proteins: another protective process? Ann N Y Acad Sci 2002; 959: 285-94.